Fri, Mar 6, 2015, 8:30 AM EST - U.S. Markets open in 1 hr.


% | $
Quotes you view appear here for quick access.

Wright Medical Group, Inc. Message Board

  • chirag_487a chirag_487a Feb 4, 2014 1:06 PM Flag

    Is anyone out there?

    Is anyone out there?

    i have not followed wmgiz since past few months, is it a good buy at this time?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • More outdated info!

      Wright Medical Group, Inc. Announces Receipt of FDA Not Approvable Letter for Augment® Bone Graft
      Company to Host Conference Call at 3:30 p.m. Central Time Today

      ARLINGTON, Tenn.--(BUSINESS WIRE)--Aug. 8, 2013-- Wright Medical Group, Inc. (NASDAQ: WMGI) today announced it received a not approvable letter from the Food & Drug Administration (FDA) in response to its Pre-Market Approval (PMA) application for Augment® Bone Graft for use as an alternative to autograft in hindfoot and ankle fusion procedures.

      In the letter, FDA states it is “concerned that the population enrolled was predominantly low risk and, therefore, may not have warranted the use of either autograft or Augment Bone Graft.” FDA went on to state it believes that “it will be necessary to perform a new clinical study that evaluates the use of Augment Bone Graft as a substitute for autograft in hindfoot and ankle fusion procedures in a well-defined high-risk target population, where the use of autograft would be clinically warranted.”

      In summary, FDA concerns included “the patient population studied in the clinical study, the amount of graft material implanted, and the uncertainty as to whether any graft material would be needed or if the use of no graft material in a fusion procedure of the hindfoot and ankle in the population studied would have achieved similar results.” FDA provided a number of additional observations about the clinical study design and results.

      “Needless to say, we are very disappointed by the FDA’s decision to issue a not approvable letter for our PMA application for Augment Bone Graft,” stated Robert Palmisano, president and chief executive officer of Wright. “This is not what we expected, as we believed that all of the FDA’s concerns as outlined in their previous not approvable letter from December 2011 had been fully and thoroughly addressed in the PMA amendment that BioMimetic submitted in June 2012. We are continuing to study the FDA’s position and expe

    • From Investors hub

      WMGIZ is a Contingent Value Right

      CVRs are given to shareholders as an additional benefit if a specified event occurs. A CVR is similar to an option. The payoff is contingent.

      WMI acquired Biomimetic.The CVRs were provided to shareholders as a "sweetner".

      The payoff for WMGIZ is two fold: (1) FDA approval of Augment® Bone Graft ($3.50) and (2) payment streams from sales revenue ($1.50 per share upon the achievement of $40 million in trailing twelve month sales for all products contributed by Biomimetic and $1.50 per share upon the achievement of $70 million in trailing twelve month sales for all products contributed by Biomimetic).

    • Sure we r here.

      Good BUY? If you like to gamble! Your betting on the come and that's always high risk/high reward.

      Hard to get any news on these 'rights"!

      Sentiment: Hold


Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Geron Corporation
NASDAQThu, Mar 5, 2015 4:00 PM EST
Foot Locker, Inc.
NYSEThu, Mar 5, 2015 4:05 PM EST